Biomarkers /
EGFR A763_Y764insFQEA
Back to Biomarkers List
Overview
Biomarker-Directed Therapies
EGFR A763_Y764insFQEA is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients.
Of the therapies with EGFR A763_Y764insFQEA as a predictive biomarker, 1 is FDA-approved and 8 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against EGFR A763_Y764insFQEA or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Single agent, or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Single agent, or in combination with bevacizumab (non-squamous only) or ramucirumab. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: EGFR T790M confers resistance to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Preferred first-line therapy, per NCCN. Also recommended as adjuvant therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR A763_Y764insFQEA serves as an inclusion eligibility criterion in 138 clinical trials, of which 90 are open and 48 are closed. Of the trials that contain EGFR A763_Y764insFQEA as an inclusion criterion, 1 is early phase 1 (0 open), 39 are phase 1 (23 open), 26 are phase 1/phase 2 (20 open), 51 are phase 2 (34 open), 4 are phase 2/phase 3 (3 open), 14 are phase 3 (9 open), 2 are phase 4 (1 open), and 1 is no phase specified (0 open).
Trials with EGFR A763_Y764insFQEA in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, lung adenocarcinoma, squamous cell lung carcinoma, and malignant solid tumor [5].
Pembrolizumab, pemetrexed, carboplatin, osimertinib, and durvalumab are the most frequent therapies in trials with EGFR A763_Y764insFQEA as an inclusion criteria [5].
Significance of EGFR A763_Y764insFQEA in Diseases
Non-Small Cell Lung Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 123 clinical trials for non-small cell lung carcinoma, of which 78 are open and 45 are closed. Of the trials that contain EGFR A763_Y764insFQEA and non-small cell lung carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 36 are phase 1 (22 open), 26 are phase 1/phase 2 (20 open), 42 are phase 2 (25 open), 4 are phase 2/phase 3 (3 open), 11 are phase 3 (7 open), 2 are phase 4 (1 open), and 1 is no phase specified (0 open) [5].
Afatinib, gefitinib, erlotinib, crizotinib, osimertinib, dacomitinib, capmatinib, cetuximab, and pembrolizumab have evidence of efficacy in patients with EGFR A763_Y764insFQEA in non-small cell lung carcinoma [5].
Malignant Solid Tumor +
EGFR A763_Y764insFQEA is an inclusion criterion in 11 clinical trials for malignant solid tumor, of which 9 are open and 2 are closed. Of the trials that contain EGFR A763_Y764insFQEA and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].
Breast Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [5].
Lung Adenocarcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 5 clinical trials for lung adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain EGFR A763_Y764insFQEA and lung adenocarcinoma as inclusion criteria, 3 are phase 2 (3 open) and 2 are phase 3 (1 open) [5].
Melanoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].
Bladder Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Glioblastoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Multiple Myeloma +
EGFR A763_Y764insFQEA is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [5].
Urothelial Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR A763_Y764insFQEA and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Anaplastic Astrocytoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Biliary Tract Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Colorectal Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR A763_Y764insFQEA and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Endometrial Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Head And Neck Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Hepatocellular Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Lung Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EGFR A763_Y764insFQEA and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Lymphoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Salivary Gland Neoplasm +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Supratentorial Neoplasm +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Mesothelioma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Adenocarcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Renal Cell Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Small Cell Lung Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Thymic Carcinoma +
EGFR A763_Y764insFQEA is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR A763_Y764insFQEA and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
